IP Library Granted Patent US 10,215,759
Granted Patent B2
US 10,215,759 · App. 15/257,517 · Granted Feb 26, 2019

Electrophysiological assays using oocytes that express human ENaC and the use of phenamil to improve the effect of ENaC enhancers in assays using membrane potential reporting dyes

Inventors: Guy Servant (San Diego, CA); Hong Chang (San Diego, CA); Cyril Redcrow (San Diego, CA); Sumita Ray (San Diego, CA); Imran Clark (Carlsbad, CA); Bryan Moyer (San Diego, CA)
Assignee: SENOMYX, INC.
G01N33/6872C12N15/85C12Q1/025G01N33/5044C12N2320/10C12N2503/02G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,215,759
App. No.
15/257,517
Granted
Feb 26, 2019
Kind
B2
Abstract

In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.

Claims (15)

1. A method of identifying a compound which modulates taste by:

(i) contacting a recombinant or isolated mammalian cell or cell population that expresses a functional human Epithelial Sodium Channel (hENaC) comprising a delta subunit which is at least 95% identical to the polypeptide encoded by SEQ ID NO:7 and an alpha and beta subunit which are respectively at least 95% identical to the polypeptides encoded by SEQ ID NO:1 and 2 with at least one compound,

(ii) identifying whether the compound modulates the activity of said functional hENaC; and

(iii) based on whether the compound modulates activity of said hENaC identifying the compound as one potentially modulating taste.

2. The method of claim 1 which includes testing the identified compound in a taste test.

3. The method of claim 1 wherein the isolated cell or cell population is human.

4. The method of claim 1 wherein the isolated cell or cell population is selected from the group consisting of MDCK, BHK, COS, NIH3T3, Swiss3T3 and CHO cells.

5. The method of claim 1 wherein the isolated cell or cell population transiently expresses the alpha (or delta), beta and gamma hENaC subunits.

6. The method of claim 1 wherein the isolated cell or cell population stably expresses the alpha (or delta), beta and gamma hENaC subunits.

7. The method of claim 1 wherein the isolated cell or cell population are comprised in a multi-well test plate device.

8. The method of claim 1 wherein the isolated cell or cell population are loaded with a membrane potential dye.

9. The method of claim 1 wherein the isolated cell or cell population is grown to about 80% confluence.

10. The method of claim 8 wherein the membrane potential dye is CC2-DMPVE , DiSBAC2(3) or ESS-CY4.

11. The method of claim 1 wherein the expressed delta subunit is encoded by the sequence in SEQ ID NO:7.

12. The method of claim 11 wherein the expressed alpha and beta subunits respectively contain the polypeptides encoded by SEQ ID NO:1 and 2.

Assignments (2)
MERGER Recorded Aug 9, 2019
From: SENOMYX, INC.
To: FIRMENICH INCORPORATED
Reel/Frame 050009/0873 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2017
From: SERVANT, GUY; CHANG, HONG; REDCROW, CYRIL; RAY, SUMITA; CLARK, IMRAN; MOYER, BRYAN
To: SENOMYX, INC.
Reel/Frame 044286/0527 →
Continuity (5)
Division 10563758
Continuation In Part 10133573 · Apr 29, 2002
Provisional Application 60485745 · Jul 10, 2003
Provisional Application 60287413 · May 1, 2001
Related Publication 20170175160A1 · Jun 22, 2017